Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.
Shea P O'ConnellEve O'ReillyAlexandra TuzovaMartyn WebbRachel HurstRobert MillsFang ZhaoBharati BapatColin S CooperAntoinette S PerryJeremy ClarkDaniel S BrewerPublished in: The Prostate (2020)
Integration of urinary biomarkers across multiple assay methods has greater diagnostic ability than either method in isolation, providing superior predictive ability of biopsy outcomes. ExoMeth represents a more holistic view of urinary biomarkers and has the potential to result in substantial changes to how patients suspected of harboring prostate cancer are diagnosed.
Keyphrases
- prostate cancer
- cell free
- dna methylation
- radical prostatectomy
- end stage renal disease
- ejection fraction
- newly diagnosed
- gene expression
- chronic kidney disease
- single cell
- genome wide
- metabolic syndrome
- high throughput
- stem cells
- electronic health record
- cell therapy
- big data
- patient reported outcomes
- bone marrow
- climate change
- artificial intelligence
- mesenchymal stem cells
- weight loss